Dmitriy S. Titov
Dmitriy S. Titov has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Elena Nikolaevna Yakusheva
Рязанский государственный медицинский университет имени академика И. П. Павлова
5 shared publications - Marina A. Maystrenko
Pavlov Ryazan State Medical University
4 shared publications - Ekaterina E. Uliteonok
Ryazan State Medical University named after Academician I.P. Pavlov, Ryazan, Russia
3 shared publications - Marina Yu. Klishchenko
Ryazan State Medical University
3 shared publications - Igor Aleksandrovich Suchkov
Ryazan State Medical University named after academician I.P. Pavlov, Ministry of Health of the Russian Federation
2 shared publications - Mikhail M. Uporov
Ryazan State Medical University
2 shared publications
Latest Publications
- 1 January 2026
- Published by FSBEI HE NSMU MOH Russia in JOURNAL of SIBERIAN MEDICAL SCIENCES
- Vol. 10 (1)
A pharmacoeconomic study of captopril, enalarpil, and lisinopril using data from the State Register of Maximum Selling Prices
Introduction. Arterial hypertension (AH) is a serious problem of modern medicine. High blood pressure significantly increases the risk of dangerous cardiovascular complications. Aim. To perform a pharmacoeconomic cost-effectiveness analysis of angiotensin-converting enzyme inhibitors (ACE inhibitors) – captopril, enalapril, and lisinopril using data from the State Register of Maximum Selling Prices. Materials and methods. Data on the clinical effectiveness of the studied ACE inhibitors was obtained from literature sources. The level of reduction of elevated blood pressure (systolic and diastolic) was considered as the criterion of clinical efficacy. The costs of pharmacotherapy were calculated based on the data from the State Register of Medicines. To perform a cost-effectiveness analysis (CEA), the cost-effectiveness ratio (CER) was calculated for captopril, lisinopril, and enalapril in order to determine the most cost-effective ACE inhibitor with the minimum CER value. The CEA was performed in 3 variants: CEA No. 1 – calculation of CER for 20 subgroups (CER separately for each dose that demonstrated clinical effectiveness); CEA No. 2 – calculation of CER separately for each dose, the price of which was used to calculate the costs; CEA No. 3 – calculation of CER for all doses simultaneously. Results. The CER values for enalapril at a daily dose of 20 mg, achieved by taking four 5 mg tablets, were statistically significantly lower than the CER values for captopril and lisinopril when assessing clinical effectiveness by normalizing systolic blood pressure (SBP). It was also found that the CER values for enalapril at a daily dose of 20 mg (8 tablets at a dose of 2,5 mg) were statistically significantly lower than the CER values for captopril and lisinopril when assessing clinical effectiviness by normalizing diastolic blood pressure (DBP). Conclusion. A cost-effectiveness analysis of ACE inhibitors showed that enalapril 20 mg/day is more cost-effective than captopril and lisinopril for normalizing SBP and DBP.
- 1 January 2026
- Published by FSBEI HE NSMU MOH Russia in JOURNAL of SIBERIAN MEDICAL SCIENCES
- Vol. 10 (1)
A pharmacoeconomic study of captopril, enalarpil, and lisinopril using data from the State Register of Maximum Selling Prices
Introduction. Arterial hypertension (AH) is a serious problem of modern medicine. High blood pressure significantly increases the risk of dangerous cardiovascular complications. Aim. To perform a pharmacoeconomic cost-effectiveness analysis of angiotensin-converting enzyme inhibitors (ACE inhibitors) – captopril, enalapril, and lisinopril using data from the State Register of Maximum Selling Prices. Materials and methods. Data on the clinical effectiveness of the studied ACE inhibitors was obtained from literature sources. The level of reduction of elevated blood pressure (systolic and diastolic) was considered as the criterion of clinical efficacy. The costs of pharmacotherapy were calculated based on the data from the State Register of Medicines. To perform a cost-effectiveness analysis (CEA), the cost-effectiveness ratio (CER) was calculated for captopril, lisinopril, and enalapril in order to determine the most cost-effective ACE inhibitor with the minimum CER value. The CEA was performed in 3 variants: CEA No. 1 – calculation of CER for 20 subgroups (CER separately for each dose that demonstrated clinical effectiveness); CEA No. 2 – calculation of CER separately for each dose, the price of which was used to calculate the costs; CEA No. 3 – calculation of CER for all doses simultaneously. Results. The CER values for enalapril at a daily dose of 20 mg, achieved by taking four 5 mg tablets, were statistically significantly lower than the CER values for captopril and lisinopril when assessing clinical effectiveness by normalizing systolic blood pressure (SBP). It was also found that the CER values for enalapril at a daily dose of 20 mg (8 tablets at a dose of 2,5 mg) were statistically significantly lower than the CER values for captopril and lisinopril when assessing clinical effectiviness by normalizing diastolic blood pressure (DBP). Conclusion. A cost-effectiveness analysis of ACE inhibitors showed that enalapril 20 mg/day is more cost-effective than captopril and lisinopril for normalizing SBP and DBP.
- Open Access
- 13 June 2025
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 32 (2) , 18-26
Comparative assessment of cardiac arrhythmias and clinical and economic analysis using remote telemetry in elderly and senile patients following dual-chamber pacemaker implantation
Aim. To compare the frequency and timing of cardiac arrhythmia detection and conduct a clinical and economic analysis of remote telemetry (RT) in elderly and senile patients following dual-chamber pacemaker (PM) implantation compared to in-person clinical follow-up over a 12-month period.Methods. A prospective study was conducted involving 92 patients (50% female), with a mean age of 71,5 years. The intervention group (n=39) was monitored remotely using the Medtronic CareLink Network, USA, with patients transmitting data monthly for one year. The control group (n=53) underwent in-person clinical follow-ups at one month and one year post-implantation. The groups were comparable in age, sex, clinical diagnoses, and complications (p>0,05). A cost-effectiveness analysis (CEA) was performed, and the cost-effectiveness ratio (CER) was calculated.Results. No statistically significant differences were observed between the experimental and control groups in the frequency of cardiac arrhythmias. However, significant differences were found in the timing of arrhythmia detection (pConclusion. The use of RT in elderly and senile patients following dual-chamber PM implantation did not show a statistical difference in arrhythmia detection rates. However, cardiac arrhythmias were diagnosed earlier in the experi mental group. The cost-effectiveness analysis demonstrated that RT requires lower financial costs to achieve a unit of effectiveness compared to in-person monitoring.
- 13 June 2025
- Published by Institute of Cardio Technics - INCART in Journal of Arrhythmology
- Vol. 32 (2) , 18-26
Open AccessComparative assessment of cardiac arrhythmias and clinical and economic analysis using remote telemetry in elderly and senile patients following dual-chamber pacemaker implantation
Aim. To compare the frequency and timing of cardiac arrhythmia detection and conduct a clinical and economic analysis of remote telemetry (RT) in elderly and senile patients following dual-chamber pacemaker (PM) implantation compared to in-person clinical follow-up over a 12-month period.Methods. A prospective study was conducted involving 92 patients (50% female), with a mean age of 71,5 years. The intervention group (n=39) was monitored remotely using the Medtronic CareLink Network, USA, with patients transmitting data monthly for one year. The control group (n=53) underwent in-person clinical follow-ups at one month and one year post-implantation. The groups were comparable in age, sex, clinical diagnoses, and complications (p>0,05). A cost-effectiveness analysis (CEA) was performed, and the cost-effectiveness ratio (CER) was calculated.Results. No statistically significant differences were observed between the experimental and control groups in the frequency of cardiac arrhythmias. However, significant differences were found in the timing of arrhythmia detection (pConclusion. The use of RT in elderly and senile patients following dual-chamber PM implantation did not show a statistical difference in arrhythmia detection rates. However, cardiac arrhythmias were diagnosed earlier in the experi mental group. The cost-effectiveness analysis demonstrated that RT requires lower financial costs to achieve a unit of effectiveness compared to in-person monitoring.
- 31 March 2024
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
- Vol. 12 (1)
World Experience in Realization of Electronic Prescription System for Medicines
INTRODUCTION: Modern healthcare is rapidly developing using electronic communication means. In many countries, electronic systems for storing and distributing personal data related to healthcare, including the exchange of electronic prescriptions, already exist or are actively being developed. CONCLUSION: Foreign experience shows that the introduction of the electronic prescription system permits to reduce the number of mistakes in the appointment and use of medical drugs helps reduce the uncontrolled and unjustifiable use of antibiotics and medicines that are subject to accounting. The electronic prescription system in corporate medical decision support systems, which not only protect the doctor from mistakes, but also speed up and facilitate his work.
- 31 March 2024
- Published by Ryazan State Medical University in Nauka Molodykh (Eruditio Juvenium)
- Vol. 12 (1)
World Experience in Realization of Electronic Prescription System for Medicines
INTRODUCTION: Modern healthcare is rapidly developing using electronic communication means. In many countries, electronic systems for storing and distributing personal data related to healthcare, including the exchange of electronic prescriptions, already exist or are actively being developed. CONCLUSION: Foreign experience shows that the introduction of the electronic prescription system permits to reduce the number of mistakes in the appointment and use of medical drugs helps reduce the uncontrolled and unjustifiable use of antibiotics and medicines that are subject to accounting. The electronic prescription system in corporate medical decision support systems, which not only protect the doctor from mistakes, but also speed up and facilitate his work.
- Open Access
- 30 December 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (4) , 596-606
Pharmacoeconomic study of fluorescent lymphography and radionuclide diagnostics methods for sentinel lymph node detection in breast cancer
Background. Sentinel lymph node (SLN) biopsy is a reliable diagnostic method used to assess the spread of the malignant process in regional lymph nodes. Currently, this method is of great importance in treatment planning for early breast cancer and allows to avoid immediate and long-term complications of lymph node dissection. SLN detection can be performed using the radionuclide method, the disadvantages of which are associated with the peculiarities of working with radiopharmaceuticals and additional costs when using them. An alternative method is fluorescence lymphography (FL) with indocyanine green.Objective: performing a pharmacoeconomical study (cost-effectiveness analysis) comparing the cost-effectiveness of methods for detecting SLN in breast cancer: radionuclide diagnosis (RD) using a radiopharmaceutical based on sodium pertechnetate [99mТс] and FL using indocyanine green (Life Sciences OCPK LLC, Russia) and "IC GOR System" device (Central Design Bureau of Information and Control Systems JSC, Russia).Material and methods. The values of the cost-effectiveness ratio (CER) were calculated and compared for the two indicated methods of detecting SLN in breast cancer. Information on the RD method clinical efficacy was taken from the published data. SLN detection by the FL method with the use of indocyanine green and domestic apparatus was performed on the basis of the Regional Clinical Oncology Dispensary (Ryazan) in 53 patients with breast cancer. To assess the reliability of the obtained results a deterministic multivariate sensitivity analysis was performed.Results. The obtained CERFL values were significantly lower than the median CERRD values by average of 43.29% (pFL was lower than CERRD by 39,40% (from 37.99% to 42.80%), and their 95% confidence intervals (CI) did not intersect. Deterministic multivariate sensitivity analysis demonstrated robustness of the obtained data to the transformation of RD cost parameters. Nevertheless the geometric mean and its 95% CI of CERRD and CERFL did not intersect under any circumstances.Conclusion. According to the results of a pharmacoeconomic study, it is more economically profitable to detect SLN in breast cancer using indocyanine green and a domestic device for FL, as its costs per unit of efficiency were 38–45% lower than for RD using a radiopharmaceutical based on sodium pertechnetate [99mТс].
- 30 December 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (4) , 596-606
Open AccessPharmacoeconomic study of fluorescent lymphography and radionuclide diagnostics methods for sentinel lymph node detection in breast cancer
Background. Sentinel lymph node (SLN) biopsy is a reliable diagnostic method used to assess the spread of the malignant process in regional lymph nodes. Currently, this method is of great importance in treatment planning for early breast cancer and allows to avoid immediate and long-term complications of lymph node dissection. SLN detection can be performed using the radionuclide method, the disadvantages of which are associated with the peculiarities of working with radiopharmaceuticals and additional costs when using them. An alternative method is fluorescence lymphography (FL) with indocyanine green.Objective: performing a pharmacoeconomical study (cost-effectiveness analysis) comparing the cost-effectiveness of methods for detecting SLN in breast cancer: radionuclide diagnosis (RD) using a radiopharmaceutical based on sodium pertechnetate [99mТс] and FL using indocyanine green (Life Sciences OCPK LLC, Russia) and "IC GOR System" device (Central Design Bureau of Information and Control Systems JSC, Russia).Material and methods. The values of the cost-effectiveness ratio (CER) were calculated and compared for the two indicated methods of detecting SLN in breast cancer. Information on the RD method clinical efficacy was taken from the published data. SLN detection by the FL method with the use of indocyanine green and domestic apparatus was performed on the basis of the Regional Clinical Oncology Dispensary (Ryazan) in 53 patients with breast cancer. To assess the reliability of the obtained results a deterministic multivariate sensitivity analysis was performed.Results. The obtained CERFL values were significantly lower than the median CERRD values by average of 43.29% (pFL was lower than CERRD by 39,40% (from 37.99% to 42.80%), and their 95% confidence intervals (CI) did not intersect. Deterministic multivariate sensitivity analysis demonstrated robustness of the obtained data to the transformation of RD cost parameters. Nevertheless the geometric mean and its 95% CI of CERRD and CERFL did not intersect under any circumstances.Conclusion. According to the results of a pharmacoeconomic study, it is more economically profitable to detect SLN in breast cancer using indocyanine green and a domestic device for FL, as its costs per unit of efficiency were 38–45% lower than for RD using a radiopharmaceutical based on sodium pertechnetate [99mТс].
- Open Access
- 22 November 2023
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 31 (4) , 535-550
Effectiveness of Different Treatment Tactics of Superficial Thrombophlebitis of Lower Limbs (with Development of Mathematical Model for Prediction of Therapeutic Effectiveness)
INTRODUCTION: The main goals of treatment of superficial thrombophlebitis of lower limbs (ST LL) can be achieved using different treatment tactics: conservative treatment, surgical intervention, and their combination. AIM: To perform a comparative analysis of the effectiveness of pharmacotherapy, crossectomy in combination with pharmacotherapy and of phlebectomy in combination with pharmacotherapy in patients with ST LL. MATERIALS AND METHODS: A comparative analysis of the effectiveness of the therapeutic tactics of ST LL was conducted (86 patients; 36 men and 50 women). Group 1 patients received only conservative treatment, group 2 patients underwent crossectomy and conservative treatment in the postoperative period, group 3 — phlebectomy in combination with conservative treatment. The clinical effectiveness of treatment was evaluated by the recurrence rate and/or progression of the disease within 3 months after treatment and the level of life quality (Chronic Venous Insufficiency Questionnaire, CIVIQ 20, visual analog scale, VAS). Based on the data obtained in the study, a mathematical model was developed to determine the maximally effective treatment method. For mathematical modeling, a ‘random forest’ method was used. RESULTS: All the studied treatment methods demonstrated a comparative clinical effectiveness. Analysis of the dynamics of the studied parameters (adjusted for gender and age of the patients) compared with their initial values within each group showed that statistically significant changes in the psychological factor were observed in the pharmacotherapy group already on the 7th control day (p = 0.024), while in the crossectomy and phlebectomy groups only on the 14th day. In the groups of pharmacotherapy (p = 0.001) and phlebectomy (p = 0.005), the improvement in terms of the social factor occurred faster than in the group of crossectomy, since statistically significant differences were found on the 7th day, and in the group of crossectomy only on the 14th day. CONCLUSION: All the groups demonstrated comparable clinical effectiveness in normalization of the quality of life and the recurrence rate and/or progression of the disease within three months after completion of treatment. On the basis of the data obtained, predictive models have been constructed that allow, based on the initial characteristics of the patient, to determine the tactics of therapy that can ensure maximum effectiveness in terms of normalization of values, reflecting the quality of life and VAS parameter.
- 22 November 2023
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 31 (4) , 535-550
Open AccessEffectiveness of Different Treatment Tactics of Superficial Thrombophlebitis of Lower Limbs (with Development of Mathematical Model for Prediction of Therapeutic Effectiveness)
INTRODUCTION: The main goals of treatment of superficial thrombophlebitis of lower limbs (ST LL) can be achieved using different treatment tactics: conservative treatment, surgical intervention, and their combination. AIM: To perform a comparative analysis of the effectiveness of pharmacotherapy, crossectomy in combination with pharmacotherapy and of phlebectomy in combination with pharmacotherapy in patients with ST LL. MATERIALS AND METHODS: A comparative analysis of the effectiveness of the therapeutic tactics of ST LL was conducted (86 patients; 36 men and 50 women). Group 1 patients received only conservative treatment, group 2 patients underwent crossectomy and conservative treatment in the postoperative period, group 3 — phlebectomy in combination with conservative treatment. The clinical effectiveness of treatment was evaluated by the recurrence rate and/or progression of the disease within 3 months after treatment and the level of life quality (Chronic Venous Insufficiency Questionnaire, CIVIQ 20, visual analog scale, VAS). Based on the data obtained in the study, a mathematical model was developed to determine the maximally effective treatment method. For mathematical modeling, a ‘random forest’ method was used. RESULTS: All the studied treatment methods demonstrated a comparative clinical effectiveness. Analysis of the dynamics of the studied parameters (adjusted for gender and age of the patients) compared with their initial values within each group showed that statistically significant changes in the psychological factor were observed in the pharmacotherapy group already on the 7th control day (p = 0.024), while in the crossectomy and phlebectomy groups only on the 14th day. In the groups of pharmacotherapy (p = 0.001) and phlebectomy (p = 0.005), the improvement in terms of the social factor occurred faster than in the group of crossectomy, since statistically significant differences were found on the 7th day, and in the group of crossectomy only on the 14th day. CONCLUSION: All the groups demonstrated comparable clinical effectiveness in normalization of the quality of life and the recurrence rate and/or progression of the disease within three months after completion of treatment. On the basis of the data obtained, predictive models have been constructed that allow, based on the initial characteristics of the patient, to determine the tactics of therapy that can ensure maximum effectiveness in terms of normalization of values, reflecting the quality of life and VAS parameter.
- Open Access
- 23 October 2023
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 68 (5-6) , 39-48
Analysis of The Antibiotic Resistance Problem
Antibiotic resistance is a global health problem. Its solution requires concerted efforts on the scale of global cooperation. Programs to prevent the development of antibiotic resistance, as well as to stimulate the development of new drugs with antimicrobial activity are implemented in a lot of countries. The use of antibacterial drugs, including inappropriate use, has increased during the COVID-19 pandemic, which may contribute to the growth of antibiotic resistance. The aim of this study is to assess the measures aimed at combating the growing antibiotic resistance in the world, analyze the market of antimicrobial drugs in the Russian Federation, as well as collect and process information on the antibiotic resistance of microorganisms that cause infectious diseases that develop against the backdrop of COVID-19. The analysis of the state register of the Russian Federation for antibacterial drugs was carried out. Mathematical and statistical processing of antibiotic resistance was performed according to the data of the European Surveillance Atlas of Infectious Diseases for Klebsiella pneumonia in relation to fluoroquinolones, aminoglycosides, third-generation cephalosporins, as well as combined resistance to these antibacterial drugs over the past sixteen years.
- 23 October 2023
- Published by Publishing House OKI in Antibiot Khimioter = Antibiotics and Chemotherapy
- Vol. 68 (5-6) , 39-48
Open AccessAnalysis of The Antibiotic Resistance Problem
Antibiotic resistance is a global health problem. Its solution requires concerted efforts on the scale of global cooperation. Programs to prevent the development of antibiotic resistance, as well as to stimulate the development of new drugs with antimicrobial activity are implemented in a lot of countries. The use of antibacterial drugs, including inappropriate use, has increased during the COVID-19 pandemic, which may contribute to the growth of antibiotic resistance. The aim of this study is to assess the measures aimed at combating the growing antibiotic resistance in the world, analyze the market of antimicrobial drugs in the Russian Federation, as well as collect and process information on the antibiotic resistance of microorganisms that cause infectious diseases that develop against the backdrop of COVID-19. The analysis of the state register of the Russian Federation for antibacterial drugs was carried out. Mathematical and statistical processing of antibiotic resistance was performed according to the data of the European Surveillance Atlas of Infectious Diseases for Klebsiella pneumonia in relation to fluoroquinolones, aminoglycosides, third-generation cephalosporins, as well as combined resistance to these antibacterial drugs over the past sixteen years.
- Open Access
- 19 July 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (2) , 210-220
Pharmacoeconomic study of various treatment options for superficial vein thrombophlebitis of lower extremities
Pharmacoeconomic study of various treatment options for superficial vein thrombophlebitis of lower extremities
- 19 July 2023
- Published by IRBIS in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
- Vol. 16 (2) , 210-220
Open AccessPharmacoeconomic study of various treatment options for superficial vein thrombophlebitis of lower extremities
Pharmacoeconomic study of various treatment options for superficial vein thrombophlebitis of lower extremities
- 7 October 2022
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 30 (3) , 423-430
Changes in the Procedure of Issuing and Circulation of Prescriptions in the Russian Federation
INTRODUCTION: The regulatory and legal framework controlling the procedure for registration and circulation of prescriptions in the Russian Federation is dynamic and changes with the level of development of digital technologies. The Ministry of Health of the Russian Federation is continuously working on improvement of the existing regulatory documents with the aim to optimize the activities of medical and pharmaceutical workers in the field of issuing prescriptions and sale of prescription drugs. The article presents an analysis of the regulatory and legal framework regulating the procedure for registration and circulation of prescriptions for medical drugs. CONCLUSIONS: On March 1, 2022, Order No. 1094n came into force, that regulates the new procedure for registration and circulation of prescriptions. The changes made to the rules are aimed at optimizing the procedure for issuing prescriptions and simplifying it for doctors. However, for a number of formulations used in the current version of the order, explanations from the Ministry of Health of the Russian Federation are desirable, or it is necessary to form a unified opinion of the professional community.
- 7 October 2022
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 30 (3) , 423-430
Changes in the Procedure of Issuing and Circulation of Prescriptions in the Russian Federation
INTRODUCTION: The regulatory and legal framework controlling the procedure for registration and circulation of prescriptions in the Russian Federation is dynamic and changes with the level of development of digital technologies. The Ministry of Health of the Russian Federation is continuously working on improvement of the existing regulatory documents with the aim to optimize the activities of medical and pharmaceutical workers in the field of issuing prescriptions and sale of prescription drugs. The article presents an analysis of the regulatory and legal framework regulating the procedure for registration and circulation of prescriptions for medical drugs. CONCLUSIONS: On March 1, 2022, Order No. 1094n came into force, that regulates the new procedure for registration and circulation of prescriptions. The changes made to the rules are aimed at optimizing the procedure for issuing prescriptions and simplifying it for doctors. However, for a number of formulations used in the current version of the order, explanations from the Ministry of Health of the Russian Federation are desirable, or it is necessary to form a unified opinion of the professional community.
- 31 March 2022
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 30 (1) , 29-38
Effect of Vildagliptin on the Level of P-Glycoprotein Expression in Normal Conditions and Alloxan–Induced Type 2 Diabetes Mellitus
INTRODUCTION: Vildagliptin is one of the drugs of choice in the treatment of type 2 diabetes mellitus (DM). In the literature review, no study has reported the effect of vildagliptin on the expression level of the transporter protein P-glycoprotein (P-gp, ABCB1 protein). AIM: To assess the in vivo effects of vildagliptin on the level of Р-gp expression in normal conditions and experimental alloxan-induced type 2 DM. MATERIALS AND METHODS: Type 2 DM was induced by a single intravenous injection of freshly prepared alloxan monohydrate solution in citrate buffer (pH = 4.0) at a dose of 80 mg/kg. Glucose content (mmol/L) was determined by the glucose oxidase method using Human kit (Germany) and insulin content (U/mL) by radioimmunoassay technique using Immunotech kit (Czech Republic). As an express method for the determination of glucose levels in the whole blood, OneTouch UltraEasy electrochemical glucose monitor (USA) was used. The level of P-gp expression in rabbit tissues (i.e., jejunum, liver, kidney, and cerebral cortex) was evaluated by the indirect histochemical method. After preliminary treatment, the histological material was embedded in paraffin. Antigens were retrieved before the immune-staining reaction. Then, the sections were incubated with primary antibodies to P-gp (ABCB1 antibody, middle region; 0.1 mL [Aviva Systems Biology ARP51326-P050, USА]). For immune staining, a polymer detection system with a peroxidase label (Leica Microsystems, Germany) was used. The cell nuclei were stained with hematoxylin. Photos of the micropreparation were captured using Canon Power Shot G5 digital camera with 400 magnification. Digital images were analyzed and processed using ImageJ and IHC Profiler plugin designed for quantitative immunohistochemical analysis. The results obtained from healthy animals, animals with alloxan-induced DM, healthy animals administered vildagliptin, and animals with modeled DM administered vildagliptin were compared. RESULTS: After day 14 of administration to healthy rabbits and day 5 of vildagliptin discontinuation (5 mg/kg), no statistically significant changes in P-gp expression in the aforementioned tissues and the levels of basal and postprandial insulin and blood glucose were noted. After the 14-day therapy of alloxan-induced type 2 DM with vildagliptin (5 mg/kg), a statistically significant recovery of expression of the P-gp expression in the jejunum, liver, and kidney was reduced due to the underlying pathology. In addition, the values of healthy rabbits and statistically significant normalization of the insulin and blood glucose levels were observed. On day 5 of drug cancellation, significant inhibition of P-gp expression in the jejunum, liver, and kidney was noted again, and there was a significant reduction of postprandial insulin and blood glucose. No significant alterations of ABCB1 protein expression in the hematoencephalic barrier were noted during the studied periods. CONCLUSION: The administration of vildagliptin (5 mg/kg) to rabbits with alloxan-induced type 2 DM promotes the recovery of P-gp expression in the jejunum, liver, and kidney, which were reduced due to the underlying pathology. Meanwhile, its administration to healthy animals had no significant effect on the expression of P-gp.
- 31 March 2022
- Published by ECO-Vector LLC in I.P. Pavlov Russian Medical Biological Herald
- Vol. 30 (1) , 29-38
Effect of Vildagliptin on the Level of P-Glycoprotein Expression in Normal Conditions and Alloxan–Induced Type 2 Diabetes Mellitus
INTRODUCTION: Vildagliptin is one of the drugs of choice in the treatment of type 2 diabetes mellitus (DM). In the literature review, no study has reported the effect of vildagliptin on the expression level of the transporter protein P-glycoprotein (P-gp, ABCB1 protein). AIM: To assess the in vivo effects of vildagliptin on the level of Р-gp expression in normal conditions and experimental alloxan-induced type 2 DM. MATERIALS AND METHODS: Type 2 DM was induced by a single intravenous injection of freshly prepared alloxan monohydrate solution in citrate buffer (pH = 4.0) at a dose of 80 mg/kg. Glucose content (mmol/L) was determined by the glucose oxidase method using Human kit (Germany) and insulin content (U/mL) by radioimmunoassay technique using Immunotech kit (Czech Republic). As an express method for the determination of glucose levels in the whole blood, OneTouch UltraEasy electrochemical glucose monitor (USA) was used. The level of P-gp expression in rabbit tissues (i.e., jejunum, liver, kidney, and cerebral cortex) was evaluated by the indirect histochemical method. After preliminary treatment, the histological material was embedded in paraffin. Antigens were retrieved before the immune-staining reaction. Then, the sections were incubated with primary antibodies to P-gp (ABCB1 antibody, middle region; 0.1 mL [Aviva Systems Biology ARP51326-P050, USА]). For immune staining, a polymer detection system with a peroxidase label (Leica Microsystems, Germany) was used. The cell nuclei were stained with hematoxylin. Photos of the micropreparation were captured using Canon Power Shot G5 digital camera with 400 magnification. Digital images were analyzed and processed using ImageJ and IHC Profiler plugin designed for quantitative immunohistochemical analysis. The results obtained from healthy animals, animals with alloxan-induced DM, healthy animals administered vildagliptin, and animals with modeled DM administered vildagliptin were compared. RESULTS: After day 14 of administration to healthy rabbits and day 5 of vildagliptin discontinuation (5 mg/kg), no statistically significant changes in P-gp expression in the aforementioned tissues and the levels of basal and postprandial insulin and blood glucose were noted. After the 14-day therapy of alloxan-induced type 2 DM with vildagliptin (5 mg/kg), a statistically significant recovery of expression of the P-gp expression in the jejunum, liver, and kidney was reduced due to the underlying pathology. In addition, the values of healthy rabbits and statistically significant normalization of the insulin and blood glucose levels were observed. On day 5 of drug cancellation, significant inhibition of P-gp expression in the jejunum, liver, and kidney was noted again, and there was a significant reduction of postprandial insulin and blood glucose. No significant alterations of ABCB1 protein expression in the hematoencephalic barrier were noted during the studied periods. CONCLUSION: The administration of vildagliptin (5 mg/kg) to rabbits with alloxan-induced type 2 DM promotes the recovery of P-gp expression in the jejunum, liver, and kidney, which were reduced due to the underlying pathology. Meanwhile, its administration to healthy animals had no significant effect on the expression of P-gp.
- 1 August 2018
- Published by Pleiades Publishing Ltd in Biohimiâ
- Vol. 83 (8) , 1148-1172
СТРУКТУРА И ФУНКЦИОНИРОВАНИЕ БЕЛКА МНОЖЕСТВЕННОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТИ 1
- 1 August 2018
- Published by Pleiades Publishing Ltd in Biohimiâ
- Vol. 83 (8) , 1148-1172
СТРУКТУРА И ФУНКЦИОНИРОВАНИЕ БЕЛКА МНОЖЕСТВЕННОЙ ЛЕКАРСТВЕННОЙ УСТОЙЧИВОСТИ 1